RxDoctor Payments Data

Brian Long, MD

Ophthalmology · Fayetteville, GANPI 1760446181

Payments from drug & device makers

$3,825in general payments, 2019–2025

Across 187 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$626
  • Novartis$363
  • Johnson & Johnson Surgical Vision, Inc.$244
  • Bausch & Lomb Americas Inc.$224
  • Kala Pharmaceuticals, Inc.$216
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,807100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,825 in reported general payments places this provider in the 65th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$442,034
Medicare patients
1,737
Services billed
3,195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost310$179,851
RestasisCyclosporine80$93,396
Cyclosporine57$41,276
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol101$26,596
Brimonidine Tartrate256$25,392
CombiganBrimonidine Tartrate/Timolol59$22,636
XiidraLifitegrast12$16,587
Travoprost74$13,590
SimbrinzaBrinzolamide/Brimonidine Tart44$13,551
Latanoprost865$11,902
Alphagan PBrimonidine Tartrate19$11,048
Timolol Maleate713$8,741
Prednisolone Acetate121$6,808
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat116$2,375
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha208$2,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$626$306,931468 claims
Bausch & Lomb Americas Inc.Xiidra$224$16,58712 claims
AlconSimbrinza$1,013$13,55144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →